fasudil has been researched along with Idiopathic Parkinson Disease in 6 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fasudil treatment significantly reduced α-Syn aggregation in vitro in a H4 cell culture model as well as in a cell-free assay." | 1.43 | Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease. ( Bähr, M; Becker, S; Dambeck, V; Eckermann, K; Fonseca-Ornelas, L; Koch, JC; Lingor, P; Lopes da Fonseca, T; Outeiro, TF; Tatenhorst, L; Tönges, L; Walle, H; Zweckstetter, M, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yan, YC | 1 |
| Li, YH | 2 |
| Xiao, BG | 2 |
| Wang, J | 1 |
| Xi, JY | 2 |
| Yu, WB | 2 |
| Ostendorf, F | 1 |
| Metzdorf, J | 1 |
| Gold, R | 1 |
| Haghikia, A | 1 |
| Tönges, L | 3 |
| Lopez-Lopez, A | 1 |
| Labandeira, CM | 1 |
| Labandeira-Garcia, JL | 1 |
| Muñoz, A | 1 |
| Tatenhorst, L | 2 |
| Saal, KA | 1 |
| Koch, JC | 2 |
| Szegő, ÉM | 1 |
| Bähr, M | 2 |
| Lingor, P | 2 |
| Eckermann, K | 1 |
| Dambeck, V | 1 |
| Fonseca-Ornelas, L | 1 |
| Walle, H | 1 |
| Lopes da Fonseca, T | 1 |
| Becker, S | 1 |
| Outeiro, TF | 1 |
| Zweckstetter, M | 1 |
| Yu, JW | 1 |
| Liu, JC | 1 |
| Wang, Q | 1 |
| Song, LJ | 1 |
| Feng, L | 1 |
| Yan, YP | 1 |
| Zhang, GX | 1 |
| Ma, CG | 1 |
6 other studies available for fasudil and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Cellular and Molecular Mechanisms Underly the Combined Treatment of Fasudil and Bone Marrow Derived-Neuronal Stem Cells in a Parkinson's Disease Mouse Model.
Topics: Animals; Bone Marrow; Bone Marrow Cells; Mice; Neural Stem Cells; Neurons; Parkinson Disease; Phosph | 2023 |
Propionic Acid and Fasudil as Treatment Against Rotenone Toxicity in an In Vitro Model of Parkinson's Disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blotting, Western; Cell Survival; Cells, Cul | 2020 |
Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Dyskinesia, Drug-Ind | 2020 |
Rho kinase inhibition by fasudil in the striatal 6-hydroxydopamine lesion mouse model of Parkinson disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adrenergic Agents; Animals; Apomorphine; Corpus Stria | 2014 |
Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; alpha-Synuclein; Amides; Animals; Brain; Carrier Prot | 2016 |
Fasudil Enhances Therapeutic Efficacy of Neural Stem Cells in the Mouse Model of MPTP-Induced Parkinson's Disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals | 2017 |